中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2062-2065

Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases

DOI: 10.3969/j.issn.1001-5256.2021.09.012

  • National Clinical Research Center for Dermatologic and Immunologic Diseases, Key Laboratory of Ministry of Education, National Key Laboratory of Difficult Severe Diseases and Rare Diseases, Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China

Research funding:

The Capital's Funds for Health Improvement and Research (2020-2-4017);

the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019XK320038);

the National Natural Science Foundation of China (82071839)

  • Received Date: 2021-08-16
  • Accepted Date: 2021-08-16
  • Published Date: 2021-09-20
    Abstract
  • IgG4-related disease (IgG4-RD) is an immune-mediated disease characterized by chronic inflammation and fibrosis of affected organs. With a deeper understanding of this disease among Chinese scholars and the rich experience in diagnosis and treatment in recent years, an expert group was organized by China Alliance for Rare Diseases and Chinese Rheumatology Association in 2020 and developed the first Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases. This consensus comprehensively summarizes the principles of the diagnosis and treatment of IgG4-RD and thus provides a basis for its diagnosis and treatment by clinicians.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699. DOI: 10.1002/art.39132.
    [2]
    ZHANG W, DONG LL, ZHU J, et al. Chinese expert consensus on the diagnosis and treatment of IgG4 related diseases[J]. Chin J Intern Med, 2021, 60(3): 192-206. DOI: 10.3760/cma.j.cn112138-20200803-00726.

    张文, 董凌莉, 朱剑, 等. IgG4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206. DOI: 10.3760/cma.j.cn112138-20200803-00726.
    [3]
    STONE JH, KHOSROSHAHI A, DESHPANDE V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations[J]. Arthritis Rheum, 2012, 64(10): 3061-3067. DOI: 10.1002/art.34593.
    [4]
    KAMISAWA T, ZEN Y, PILLAI S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976): 1460-1471. DOI: 10.1016/S0140-6736(14)60720-0.
    [5]
    LIU Y, XUE M, WANG Z, et al. Salivary gland involvement disparities in clinical characteristics of IgG4-related disease: A retrospective study of 428 patients[J]. Rheumatology (Oxford), 2020, 59(3): 634-640. DOI: 10.1093/rheumatology/kez280.
    [6]
    LI W, CHEN Y, SUN ZP, et al. Clinicopathological characteristics of immunoglobulin G4-related sialadenitis[J]. Arthritis Res Ther, 2015, 17(1): 186. DOI: 10.1186/s13075-015-0698-y.
    [7]
    UMEHARA H, OKAZAKI K, MASAKI Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1): 21-30. DOI: 10.1007/s10165-011-0571-z.
    [8]
    WALLACE ZS, NADEN RP, CHARI S, et al. The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4-related disease[J]. Arthritis Rheumatol, 2020, 72(1): 7-19. DOI: 10.1002/art.41120.
    [9]
    HAMANO H, KAWA S, HORIUCHI A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738. DOI: 10.1056/NEJM200103083441005.
    [10]
    CARRUTHERS MN, KHOSROSHAHI A, AUGUSTIN T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(1): 14-18. DOI: 10.1136/annrheumdis-2013-204907.
    [11]
    WANG Y, GUAN Z, GAO D, et al. The value of (18)F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics[J]. Semin Arthritis Rheum, 2018, 47(4): 593-600. DOI: 10.1016/j.semarthrit.2017.07.011.
    [12]
    ZHANG J, CHEN H, MA Y, et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: A prospective cohort study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(8): 1624-1634. DOI: 10.1007/s00259-014-2729-3.
    [13]
    ZHAO Z, WANG Y, GUAN Z, et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases[J]. Clin Exp Rheumatol, 2016, 34(1): 119-125. http://www.ncbi.nlm.nih.gov/pubmed/26842851
    [14]
    DESHPANDE V, ZEN Y, CHAN JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012, 25(9): 1181-1192. DOI: 10.1038/modpathol.2012.72.
    [15]
    ARORA K, RIVERA M, TING DT, et al. The histological diagnosis of IgG4-related disease on small biopsies: Challenges and pitfalls[J]. Histopathology, 2019, 74(5): 688-698. DOI: 10.1111/his.13787.
    [16]
    CAMPBELL SN, RUBIO E, LOSCHNER AL. Clinical review of pulmonary manifestations of IgG4-related disease[J]. Ann Am Thorac Soc, 2014, 11(9): 1466-1475. DOI: 10.1513/AnnalsATS.201403-128FR.
    [17]
    WANG ZQ, LIU YY, ZHANG X, et al. Analysis of the clinical features and misdiagnosis reasons of 17 patients misdiagnosed with IgG4-related disease[J]. J Peking Univ(Health Sci), 2019, 51(6): 1025-1031. DOI: 10.19723/j.issn.1671-167X.2019.06.008.

    王子乔, 刘燕鹰, 张霞, 等. 17例误诊为IgG4相关疾病患者的临床特点及误诊原因分析[J]. 北京大学学报(医学版), 2019, 51(6): 1025-1031. DOI: 10.19723/j.issn.1671-167X.2019.06.008.
    [18]
    HONG X, LI W, XIE XY, et al. Differential diagnosis of IgG4-related sialadenitis, primary Sjögren syndrome, and chronic obstructive submandibular sialadenitis[J]. Br J Oral Maxillofac Surg, 2017, 55(2): 179-184. DOI: 10.1016/j.bjoms.2016.10.021.
    [19]
    BAI Z, CHEN Y, CHEN X, et al. A medical mirroring: Chronic myelomonocytic leukemia mimicking immunoglobulin G4-related disease[J]. Am J Transl Res, 2019, 11(7): 4561-4567. http://www.researchgate.net/publication/335099953_A_medical_mirroring_chronic_myelomonocytic_leukemia_mimicking_immunoglobulin_G4-related_disease
    [20]
    WALLACE ZS, KHOSROSHAHI A, CARRUTHERS MD, et al. An international multispecialty validation study of the IgG4-related disease responder index[J]. Arthritis Care Res (Hoboken), 2018, 70(11): 1671-1678. DOI: 10.1002/acr.23543.
    [21]
    ZHANG W, STONE J. Management of IgG4 related disease[J]. The Lancet Rheumatol, 2019, 1(1): e55-e65. DOI: https://doi.org/ 10.1016/S2665-9913(19)30017-7.
    [22]
    MIKI M, FUJIMORI N, OONO T, et al. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients[J]. J Dig Dis, 2019, 20(3): 152-158. DOI: 10.1111/1751-2980.12708.
    [23]
    BACKHUS J, SEUFFERLEIN T, PERKHOFER L, et al. IgG4-related diseases in the gastrointestinal tract: Clinical presentation, diagnosis and treatment challenges[J]. Digestion, 2019, 100(1): 1-14. DOI: 10.1159/000492814.
    [24]
    OKAZAKI K, UCHIDA K. Current perspectives on autoimmune pancreatitis and IgG4-related disease[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2018, 94(10): 412-427. DOI: 10.2183/pjab.94.027.
    [25]
    OKAZAKI K, CHARI ST, FRULLONI L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1): 1-6. DOI: 10.1016/j.pan.2016.12.003.
    [26]
    KAMISAWA T, NAKAZAWA T, TAZUMA S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2019, 26(1): 9-42. DOI: 10.1002/jhbp.596.
    [27]
    EBBO M, DANIEL L, PAVIC M, et al. IgG4-related systemic disease: Features and treatment response in a French cohort: Results of a multicenter registry[J]. Medicine (Baltimore), 2012, 91(1): 49-56. DOI: 10.1097/MD.0b013e3182433d77.
    [28]
    RAINA A, YADAV D, KRASINSKAS AM, et al. Evaluation and management of autoimmune pancreatitis: Experience at a large US center[J]. Am J Gastroenterol, 2009, 104(9): 2295-2306. DOI: 10.1038/ajg.2009.325.
    [29]
    WU Q, CHANG J, CHEN H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: A preliminary randomized controlled trial[J]. Int J Rheum Dis, 2017, 20(5): 639-646. DOI: 10.1111/1756-185X.13088.
    [30]
    WALLACE ZS, MATTOO H, MAHAJAN VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab[J]. Rheumatology (Oxford), 2016, 55(6): 1000-1008. DOI: 10.1093/rheumatology/kev438.
    [31]
    MASAMUNE A, NISHIMORI I, KIKUTA K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J]. Gut, 2017, 66(3): 487-494. DOI: 10.1136/gutjnl-2016-312049.
    [32]
    OMAR D, CHEN Y, CONG Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: A systematic review and network meta-analysis[J]. Rheumatology (Oxford), 2020, 59(4): 718-726. DOI: 10.1093/rheumatology/kez380.
    [33]
    WANG Y, LI K, GAO D, et al. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: A retrospective study and literature review[J]. Intern Med J, 2017, 47(6): 680-689. DOI: 10.1111/imj.13430.
    [34]
    YUNYUN F, YU C, PANPAN Z, et al. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J]. Sci Rep, 2017, 7(1): 6195. DOI: 10.1038/s41598-017-06520-5.
    [35]
    ZHANG P, GONG Y, LIU Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial[J]. Int J Rheum Dis, 2019, 22(8): 1479-1488. DOI: 10.1111/1756-185X.13633.
    [36]
    HONG X, ZHANG YY, LI W, et al. Treatment of immunoglobulin G4-related sialadenitis: Outcomes of glucocorticoid therapy combined with steroid-sparing agents[J]. Arthritis Res Ther, 2018, 20(1): 12. DOI: 10.1186/s13075-017-1507-6.
    [37]
    CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al. Rituximab for IgG4-related disease: A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6): 1171-1177. DOI: 10.1136/annrheumdis-2014-206605.
    [38]
    XIN L, MENG QQ, HU LH, et al. Prediction and management for relapse of type 1 autoimmune pancreatitis after initial steroid treatment: A long-term follow-up from China[J]. Pancreas, 2018, 47(9): 1110-1114. DOI: 10.1097/MPA.0000000000001147.
    [39]
    LIU Y, ZENG Q, ZHU L, et al. Relapse predictors and serologically unstable condition of IgG4-related disease: A large Chinese cohort[J]. Rheumatology (Oxford), 2020, 59(8): 2115-2123. DOI: 10.1093/rheumatology/kez669.
    [40]
    PENG Y, LI JQ, ZHANG PP, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: A long-term cohort study[J]. J Intern Med, 2019, 286(5): 542-552. DOI: 10.1111/joim.12942.
    [41]
    HART PA, KAMISAWA T, BRUGGE WR, et al. Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis[J]. Gut, 2013, 62(12): 1771-1776. DOI: 10.1136/gutjnl-2012-303617.
    [42]
    PENG L, ZHANG P, LI J, et al. IgG4-related aortitis/periaortitis and periarteritis: A distinct spectrum of IgG4-related disease[J]. Arthritis Res Ther, 2020, 22(1): 103. DOI: 10.1186/s13075-020-02197-w.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1486) PDF downloads(468) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return